NASDAQ:RVNC
Revance Therapeutics Stock News
$2.84
-0.0500 (-1.73%)
At Close: May 31, 2024
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?
12:06pm, Monday, 22'nd Mar 2021
Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
05:13am, Wednesday, 24'th Feb 2021
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is proje
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript
10:45pm, Monday, 22'nd Feb 2021
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q4 2020 Results - Earnings Call Transcript
Recap: Revance Therapeutics Q4 Earnings
05:25pm, Monday, 22'nd Feb 2021
Shares of Revance Therapeutics (NASDAQ:RVNC) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 25.25% year over year to ($1.24), which
Revance Therapeutics's Earnings Outlook
10:40am, Friday, 19'th Feb 2021
On Monday, February 22, Revance Therapeutics (NASDAQ:RVNC) will release its latest earnings report. Benzinga's outlook for Revance Therapeutics is included in the following report.
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
01:31pm, Friday, 27'th Nov 2020
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
10:42pm, Monday, 09'th Nov 2020
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2020 Results - Earnings Call Transcript
Recap: Revance Therapeutics Q3 Earnings
05:16pm, Monday, 09'th Nov 2020
Shares of Revance Therapeutics (NASDAQ:RVNC) decreased 8.62% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 39.58% year over year to ($1.
